Drug Profile
Antibody-drug conjugate - Xintela
Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Xintela
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Glioblastoma
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Cancer in Sweden (Parenteral)
- 28 May 2020 No recent reports of development identified for preclinical development in Glioblastoma in Sweden (Parenteral)
- 21 Aug 2018 Antibody-drug conjugate - Xintela is available for licensing as of 21 Aug 2018. www.xintela.se